^
    Apply
    Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax (NCT07471841)
    Phase 2
    Timothy Pardee
    Not yet recruiting
    Last update posted :
    03/13/2026
    Initiation :
    05/01/2026
    Primary completion :
    06/01/2028
    Completion :
    06/01/2029
    IDH1
    |
    IDH1 mutation
    |
    Venclexta (venetoclax) • azacitidine • Rezlidhia (olutasidenib)
    Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study) (NCT07183878)
    Phase N/A
    First Affiliated Hospital of Zhejiang University
    Recruiting
    Last update posted :
    09/19/2025
    Initiation :
    08/20/2025
    Primary completion :
    08/20/2027
    Completion :
    08/20/2028
    BCL2
    |
    Venclexta (venetoclax) • cyclophosphamide
    Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML (CHANCE) (NCT07172204)
    Phase 2
    First Affiliated Hospital of Zhejiang University
    Recruiting
    Last update posted :
    09/15/2025
    Initiation :
    08/15/2025
    Primary completion :
    07/31/2027
    Completion :
    07/31/2029
    BCL2
    |
    Venclexta (venetoclax) • cytarabine • azacitidine
    Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy (EVOLVE 1) (NCT07075016)
    Phase 3
    Stichting Hemato-Oncologie voor Volwassenen Ned...
    Not yet recruiting
    Last update posted :
    07/20/2025
    Initiation :
    07/01/2025
    Primary completion :
    12/01/2028
    Completion :
    03/01/2029
    IDH1
    |
    IDH1 mutation
    |
    Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib)
    Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients (NCT07039877)
    Phase 2
    Hospital Universitario Dr. Jose E. Gonzalez
    Recruiting
    Last update posted :
    06/26/2025
    Initiation :
    01/02/2025
    Primary completion :
    02/28/2026
    Completion :
    04/30/2026
    BCL2
    |
    Venclexta (venetoclax) • bortezomib • itraconazole
    Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab (MAVRiC) (NCT07024706)
    Phase 2
    AstraZeneca
    Not yet recruiting
    Last update posted :
    06/17/2025
    Initiation :
    09/30/2025
    Primary completion :
    11/30/2032
    Completion :
    11/30/2032
    BCL2
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations (NCT07012447)
    Phase 2
    yuejun Liu
    Recruiting
    Last update posted :
    06/10/2025
    Initiation :
    04/01/2025
    Primary completion :
    04/01/2027
    Completion :
    05/01/2028
    BCL2
    |
    Venclexta (venetoclax) • cytarabine • azacitidine
    Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML (NCT07007312)
    Phase 3
    Kura Oncology, Inc.
    Not yet recruiting
    Last update posted :
    06/05/2025
    Initiation :
    09/01/2025
    Primary completion :
    11/01/2031
    Completion :
    11/01/2031
    NPM1
    |
    Venclexta (venetoclax) • cytarabine • daunorubicin • Komzifti (ziftomenib)
    Use of Venetoclax , AML , Sohag , Egypt (NCT06993883)
    Phase N/A
    Sohag University
    Completed
    Last update posted :
    05/29/2025
    Initiation :
    03/01/2023
    Primary completion :
    04/30/2025
    Completion :
    04/30/2025
    BCL2
    |
    Venclexta (venetoclax)
    Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study (NCT04269902)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/02/2021
    Primary completion :
    10/01/2028
    Completion :
    10/01/2028
    TP53 • IGH
    |
    TP53 mutation • IGH mutation
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab)
    IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia (IMGN632-0802) (NCT04086264)
    Phase 1/2
    AbbVie
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/06/2019
    Primary completion :
    02/01/2027
    Completion :
    02/01/2027
    IL3RA
    |
    CD123 positive • IL3RA positive
    |
    Venclexta (venetoclax) • azacitidine • decitabine • Decnupaz (pivekimab sunirine-pvzy)
    Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia (NCT03041688)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/08/2018
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    TP53 • CD4
    |
    TP53 mutation • Chr del(17p) • TP53 wild-type
    |
    Venclexta (venetoclax) • azacitidine • decitabine • navtemadlin (KRT-232)